Cargando…

Effects of escitalopram with a Chinese traditional compound Jiuweizhenxin-keli on mismatch negativity and P50 in patients with major depressive disorders

OBJECTIVE: The objective of this study was to investigate the therapeutic effects of escitalopram in conjunction with Jiuweizhenxin-keli on neuroelectrophysiology in patients with major depressive disorders (MDD). PATIENTS AND METHODS: Patients with depressive episode of MDD according to the criteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuang, Weihong, Tian, Liantian, Yue, Lili, Li, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977078/ https://www.ncbi.nlm.nih.gov/pubmed/27536116 http://dx.doi.org/10.2147/NDT.S104020

Ejemplares similares

Identification of Target Genes of Antiarrhythmic Traditional Chinese Medicine Wenxin Keli
por: Yao, Yusi, et al.
Publicado: (2020)

Trends in the prevalence of cognitive impairment in Chinese older adults: based on the Chinese Longitudinal Healthy Longevity Survey cohorts from 1998 to 2014
por: Kuang, Weihong, et al.
Publicado: (2020)

Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011)

Wenxin Keli for the Treatment of Arrhythmia—Systems Pharmacology and In Vivo Pharmacological Assessment
por: Li, Xiaofeng, et al.
Publicado: (2021)

Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study
por: Wade, Alan G, et al.
Publicado: (2011)

Effect of Escitalopram on White Blood Cells in Patients With Major Depression
por: Canan, Fatih, et al.
Publicado: (2009)

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
por: Mencacci, Claudio, et al.
Publicado: (2013)

Screening and Identification of Cardioprotective Compounds From Wenxin Keli by Activity Index Approach and in vivo Zebrafish Model
por: Liu, Hao, et al.
Publicado: (2018)

Growth Inhibition and Induction of Apoptosis in SHG-44 Glioma Cells by Chinese Medicine Formula “Pingliu Keli”
por: Cao, Peng, et al.
Publicado: (2011)

Efficacy of escitalopram monotherapy in the treatment of major depressive disorder: A pooled analysis of 4 Chinese clinical trials
por: Li, Guanjun, et al.
Publicado: (2017)

Mismatch Negativity of Sad Syllables Is Absent in Patients with Major Depressive Disorder
por: Pang, Xiaomei, et al.
Publicado: (2014)

Systematic review and meta-analysis of randomized controlled trials on Wenxin keli
por: Wang, Xiaoyi, et al.
Publicado: (2016)

Therapeutic Effects of Wenxin Keli in Cardiovascular Diseases: An Experimental and Mechanism Overview
por: Tian, Guihua, et al.
Publicado: (2018)

An Overview of Systematic Reviews on the Effectiveness of Wenxin Keli in the Treatment of Atrial Fibrillation
por: Wang, Yuanping, et al.
Publicado: (2022)

Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression
por: Leonard, Brian, et al.
Publicado: (2010)

ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
por: Singh, A B, et al.
Publicado: (2012)

Mismatch Negativity and P50 Sensory Gating in Abstinent Former Cannabis Users
por: Broyd, Samantha J., et al.
Publicado: (2016)

The Effect of Wenxin Keli on the mRNA Expression Profile of Rabbits with Myocardial Infarction
por: Zheng, Min, et al.
Publicado: (2016)

Wenxin Keli for atrial fibrillation: Protocol for a systematic review and meta-analysis
por: He, Zhuogen, et al.
Publicado: (2018)

3D-QSAR Design of New Escitalopram Derivatives for the Treatment of Major Depressive Disorders
por: Avram, Speranta, et al.
Publicado: (2010)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression
por: Bernini de Brito, Rodrigo, et al.
Publicado: (2020)

An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2022)

Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study
por: Jeong, Jong-Hyun, et al.
Publicado: (2015)

Neurophysiological Biomarkers in Schizophrenia—P50, Mismatch Negativity, and TMS-EMG and TMS-EEG
por: Kim, Helena K., et al.
Publicado: (2020)

Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability
por: Kirino, Eiji
Publicado: (2012)

Comparing the Effects of Bupropion and Escitalopram on Excessive Internet Game Play in Patients with Major Depressive Disorder
por: Nam, Beomwoo, et al.
Publicado: (2017)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton, Benchalak, et al.
Publicado: (2018)

Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram/escitalopram in major depression
por: MahmoudianDehkordi, Siamak, et al.
Publicado: (2021)

Fabrication and Characterization of Fast-Dissolving Films Containing Escitalopram/Quetiapine for the Treatment of Major Depressive Disorder
por: Alkahtani, Manal E., et al.
Publicado: (2021)

Escitalopram-induced akathisia in a patient with major depressive disorder: A rare case report
por: Arshad, Hareem, et al.
Publicado: (2022)

Tissue-Specific Oxysterols as Predictors of Antidepressant (Escitalopram) Treatment Response in Patients With Major Depressive Disorder
por: Sun, Zuoli, et al.
Publicado: (2023)

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
por: Wang, Gang, et al.
Publicado: (2018)

Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
por: Jiang, Kaida, et al.
Publicado: (2017)

Depression in Acromegaly Treated with Escitalopram and Cognitive Therapy
por: De Sousa, Avinash
Publicado: (2009)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Escitalopram induced mania
por: Parker, Shubangi, et al.
Publicado: (2007)

Escitalopram in patients with psoriasis
por: Artemieva, M., et al.
Publicado: (2021)

Escitalopram Induced Angioedema
por: Conde, Samantha L, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ukbp9j4ienjevdlkp170lir0ig